AGIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Agios Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -84.62%.
As of today (2024-12-12), Agios Pharmaceuticals's WACC % is 7.82%. Agios Pharmaceuticals's ROC % is -116.85% (calculated using TTM income statement data). Agios Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for Agios Pharmaceuticals's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROC % | Get a 7-Day Free Trial | -102.87 | -112.28 | -110.17 | -92.39 | -135.17 |
Agios Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
ROC % | Get a 7-Day Free Trial | -117.88 | -179.71 | -203.27 | -217.28 | -84.62 |
Agios Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:
ROC % (A: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2022 ) | + | Invested Capital (A: Dec. 2023 )) | / count ) |
= | -391.487 * ( 1 - 0% ) | / | ( (437.714 | + | 141.523) | / 2 ) |
= | -391.487 | / | 289.6185 | |||
= | -135.17 % |
where
Invested Capital | (A: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1238.718 | - | 30.861 | - | ( 783.119 | - | max(0, 62.629 | - | 832.772 | + | 783.119 | )) |
= | 437.714 |
Invested Capital | (A: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 937.118 | - | 29.715 | - | ( 776.928 | - | max(0, 67.955 | - | 833.835 | + | 776.928 | )) |
= | 141.523 |
Agios Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:
ROC % (Q: Sep. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Jun. 2024 ) | + | Invested Capital (Q: Sep. 2024 )) | / count ) |
= | -411.244 * ( 1 - 5.31% ) | / | ( (168.761 | + | 751.61) | / 2 ) |
= | -389.4069436 | / | 460.1855 | |||
= | -84.62 % |
where
Invested Capital | (Q: Jun. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 773.063 | - | 34.812 | - | ( 569.892 | - | max(0, 62.637 | - | 632.127 | + | 569.892 | )) |
= | 168.761 |
Invested Capital | (Q: Sep. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1791.794 | - | 85.446 | - | ( 1004.757 | - | max(0, 119.451 | - | 1074.189 | + | 1004.757 | )) |
= | 751.61 |
Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (NAS:AGIO) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Agios Pharmaceuticals's WACC % is 7.82%. Agios Pharmaceuticals's ROC % is -116.85% (calculated using TTM income statement data). Agios Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Agios Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Rahul D. Ballal | director | 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116 |
Washburn Theodore James Jr. | officer: Principal Accounting Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
James William Burns | officer: Chief Legal Officer | C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Cecilia Jones | officer: Chief Financial Officer | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Brian Goff | director, officer: Chief Executive Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Sarah Gheuens | officer: Chief Medical Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jacqualyn A Fouse | director | C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108 |
Kaye I Foster-cheek | director | JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
David P Schenkein | director, 10 percent owner, officer: Chief Executive Officer | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Tsveta Milanova | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139 |
Jeffrey D Capello | director | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Catherine E. Owen | director | 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Richa Poddar | officer: Chief Commercial Officer | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Carman Alenson | officer: Principal Accounting Officer | 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired • 05-30-2024
By Marketwired • 06-03-2024
By GuruFocus Research • 08-03-2024
By Marketwired • 08-01-2024
By Marketwired • 05-14-2024
By GlobeNewswire • 08-06-2024
By GuruFocus Research • 08-03-2024
By GuruFocus Research • 06-07-2024
By GuruFocus Research • 08-01-2024
By Marketwired • 10-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.